My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

81.14 +0.05 (+0.06%)
Official Closing Price Updated: 6:30 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,707,767
Open 80.98
Bid (Size) 81.45 (1)
Ask (Size) 81.60 (10)
Prev. Close 81.09
Today's Range 80.80 - 82.25
52wk Range 73.31 - 119.38
Shares Outstanding 2,531,374,696
Dividend Yield 3.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property

Performance

YTD
-18.2%
-18.2%
1 Month
-3.7%
-3.7%
3 Month
+3.7%
+3.7%
6 Month
-14.3%
-14.3%
1 Year
-31.2%
-31.2%

More News

Read More
Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots
Via Benzinga
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Via Stocktwits
Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50
Via Stocktwits
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
Via MarketMinute
Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances
Via Chartmill
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
From Daiichi Sankyo
Via Business Wire
2 Healthcare Dividend Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen
Via Chartmill
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
Via Benzinga
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data
Via Benzinga
CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
From Merck & Co., Inc.
Via Business Wire
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Via Investor's Business Daily
1 Profitable Stock to Own for Decades and 2 We Turn Down
Via StockStory
Topics Economy
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Via Benzinga
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed
Via Benzinga
Topics Government
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer
Via Benzinga
3 Things You Need to Know if You Buy Pfizer Today
Via The Motley Fool
Topics Intellectual Property
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements
Via Benzinga
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster'
Via Benzinga
Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades
Via Benzinga
This Merck Pill Promises Powerful Cholesterol Reduction Without Injections
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 81.14
When was Merck & Co last traded?
The last trade of Merck & Co was at 09/17/25 06:30 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 205.40B
How many shares of Merck & Co are outstanding?
Merck & Co has 205B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.